Checkpoint Therapeutics Newsroom

Express News | FDA Approves Cosibelimab-Ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma - Website

BreakingsDec 14 07:03

Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Raises Target Price to $7

Futu NewsDec 16 22:31 · Ratings

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

BenzingaDec 16 22:22

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

WSJDec 14 08:09

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (Cosibelimab-ipdl)

GlobeNewswireDec 14 07:15

Express News | FDA: Approval of Cosibelimab-Ipdl (Unloxcyt) Granted to Checkpoint Therapeutics

BreakingsDec 14 07:04

Trading Halt: Halted at 5:26:59 P.m. ET - Trading Halt: Halt News Pending

BenzingaDec 14 06:27

FDA Decision On Checkpoint Therapeutics' Cosibelimab Due On Dec.28 - Will Second Time Be The Charm?

RTTNewsDec 12 17:17

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

PR NewswireDec 2 23:18

Checkpoint Therapeutics Analyst Ratings

BenzingaNov 15 02:25 · Ratings

H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20

Futu NewsNov 14 19:31 · Ratings

Optimistic Buy Rating for Checkpoint Therapeutics Driven by Strong Financial Position and Strategic Collaborations

TipRanksNov 14 19:16 · Ratings

Checkpoint Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 05:48 · Announcements

Checkpoint Therapeutics | 8-K: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

SECNov 13 05:46

Express News | Checkpoint Therapeutics Inc Qtrly Shr Loss $0.23

BreakingsNov 13 05:35

Express News | Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

BreakingsNov 13 05:30

Press Release: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Dow JonesNov 13 05:30

HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $20 Price Target

BenzingaSep 17 01:29 · Ratings

H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20

H.C. Wainwright analyst Joseph Pantginis maintains $Checkpoint Therapeutics(CKPT.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success

Futu NewsSep 16 23:31 · Ratings

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Fortress Biotech Inc Series A PSep 16 12:00